Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:activities |
TNF inhibitor
|
| gptkbp:approves |
gptkb:2002
gptkb:FDA |
| gptkbp:availability |
available in many countries worldwide
|
| gptkbp:category |
B
|
| gptkbp:clinical_trial |
approximately 62%
Amgen's Amjevita Boehringer Ingelheim's Cyltezo Pfizer's Abrilada Sandoz's Hyrimoz ongoing studies for various autoimmune diseases |
| gptkbp:contraindication |
active infections
hypersensitivity to adalimumab |
| gptkbp:developed_by |
gptkb:Abb_Vie
|
| gptkbp:dosage_form |
auto-injector
pre-filled syringe |
| gptkbp:education |
patients should be educated on signs of infection
|
| gptkbp:financial_performance |
up to 14 days at room temperature
|
| gptkbp:frequency |
every two weeks or every four weeks
|
| https://www.w3.org/2000/01/rdf-schema#label |
adalimumab
|
| gptkbp:invention |
gptkb:2023
|
| gptkbp:is_monitored_by |
regular monitoring for infections and liver function
|
| gptkbp:is_used_for |
gptkb:Crohn's_disease
gptkb:ulcerative_colitis gptkb:rheumatoid_arthritis gptkb:ankylosing_spondylitis psoriasis |
| gptkbp:lifespan |
approximately 15 days
|
| gptkbp:manager |
subcutaneous injection
|
| gptkbp:market |
dominant in the autoimmune market
|
| gptkbp:marketed_as |
gptkb:Humira
|
| gptkbp:metabolism |
proteolytic degradation
|
| gptkbp:pharmacokinetics |
ongoing monitoring for safety post-marketing
|
| gptkbp:population |
adults and children over 2 years old
|
| gptkbp:price |
high cost compared to traditional therapies
|
| gptkbp:provides_information_on |
recommended in treatment guidelines for several conditions
|
| gptkbp:research_focus |
long-term safety and efficacy
|
| gptkbp:rounds |
via the reticuloendothelial system
|
| gptkbp:scholarships |
available for financial assistance
|
| gptkbp:side_effect |
headache
nausea heart failure increased risk of infections injection site reactions serious infections liver problems malignancies improves quality of life in patients |
| gptkbp:storage |
refrigerated at 2-8° C
|
| gptkbp:treatment |
for moderate to severe rheumatoid arthritis
with methotrexate |
| gptkbp:website |
subcutaneous injection technique is important
|
| gptkbp:bfsParent |
gptkb:Humira
|
| gptkbp:bfsLayer |
4
|